Chairperson
Harold J. Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Brigham & Women’s Hospital
Boston, Massachusetts

Dr. Harold J. Burstein is an Associate Professor of Medicine at Harvard Medical School, and a Medical Oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital.  Dr. Burstein’s clinical research interests include novel treatments for early and advanced stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. His representative publications can be found in The New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the National Comprehensive Cancer Network® breast cancer panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the American Society of Clinical Oncology guidelines committee on endocrine therapy for breast cancer. Dr. Burstein is an Associate Editor for cancer education at the Journal of Clinical Oncology. 

Dr. Burstein earned an MD degree and a PhD degree in immunology at Harvard Medical School. He earned an MS degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber Cancer Institute.

DISCLOSURE OF CONFLICTS OF INTEREST
Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Harold J. Burstein, MD, PhD, has no real or apparent conflicts of interest to report.

The following CPEA planners and managers, Amanda Glazar, PhD, and Andrea Funk, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Linda Gracie-King, MS; Deborah Middleton, MS; and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


Faculty 

Carlos L. Arteaga, MD
Donna S. Hall Chair in Breast Cancer Research
American Cancer Society Clinical Research Professor
Professor of Medicine and Cancer Biology
Director, Center for Cancer Targeted Therapies
Director, Breast Cancer Program
Associate Director for Clinical Research
Vanderbilt-Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Dr. Carlos L. Arteaga is the Donna S. Hall Chairman in Breast Cancer Research at the Vanderbilt-Ingram Cancer Center and serves as Professor of Medicine and Cancer Biology at Vanderbilt University in Nashville, Tennessee. He is Director of the Center for Cancer Targeted Therapies and the Breast Cancer Program at Vanderbilt-Ingram Cancer Center, where he also serves as Associate Director for Translational/Clinical Research. Dr. Arteaga has approximately 300 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. Since 2002, he has directed the National Cancer Institute (NCI)-funded Vanderbilt Breast Cancer SPORE where he co-leads several investigator-initiated clinical trials. His research is funded by the NCI, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer, and the Susan G. Komen for the Cure and Breast Cancer Research foundations.

Dr. Arteaga is a member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005). He served as member of the Experimental Therapeutics-2 NIH Study Section (1998–2003), the NCI Board of Scientific Counselors (1999-2004), NCI Parent Subcommittee A for review of Cancer Centers (2004–2008), the Breast Core Committee of the Eastern Cooperative Oncology Group, and the Board of Directors of the American Association for Cancer Research (AACR; 2004–2007), for which he is currently President. He has also received numerous awards for his work. He was elected Fellow of the American Association for the Advancement of Science in 2013 and Fellow of the AACR Academy in 2015, and serves on the Scientific Advisory Board of the Komen Foundation. Dr. Arteaga has chaired the AACR Special Conference “Advances in Breast Cancer Research” since 2003 and has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. He served in various editorial roles for journals. 

Dr. Arteaga earned an MD degree from the University of Guayaquil in Ecuador. He trained in internal medical and medical oncology at Emory University in Atlanta, Georgia and at the University of Texas Health Sciences Center - San Antonio, respectively. 

DISCLOSURE OF CONFLICTS OF INTEREST
Carlos L. Arteaga, MD, reported a financial interest/relationship or affiliation in the form of Research grant: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; PUMA Biotechnology; U3 Pharma-Daichi; Consulting/Speaker fee: AstraZeneca Pharmaceuticals LP; Clovis Oncology; Eli Lilly and Company; Kiyatek; Monogram Biosciences (LabCorp); Novartis Pharmaceuticals Corporation; Roche USA; Seragon Pharmaceuticals Inc.; Susan G. Komen; Stocks: Provista Pharmaceuticals, Inc.


Maura N. Dickler, MD
Associate Member, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Section Head, Endocrine Therapy Clinical Research Program
Associate Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Dr. Maura N. Dickler is an Associate Member at Memorial Sloan Kettering Cancer Center on the Breast Medicine Service, and an Associate Professor of Medicine at the Weill Medical College of Cornell University.  Dr. Dickler’s clinical research interests have focused on developing new therapeutic strategies for the treatment of estrogen receptor–positive breast cancer. In addition, she is also studying the effects of breast cancer therapy on ovarian reserve in premenopausal women, and the impact of therapy on the sexual health of pre- and postmenopausal women. She serves on the editorial board of several journals including the Journal of Clinical Oncology and Endocrine-Related Cancers. Dr. Dickler serves on the Alliance Breast Cancer Committee and on the American Society of Clinical Oncology guidelines committee for endocrine therapy for the treatment of metastatic breast cancer. 

Dr. Dickler earned an MD degree at the University of Chicago Pritzker School of Medicine. She completed her internship and residency training at the University of Chicago hospitals, followed by a fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center in New York.

DISCLOSURE OF CONFLICTS OF INTEREST
Maura N. Dickler, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Genentech/Roche; Novartis Pharmaceuticals Corporation; Pfizer, Inc.


Richard S. Finn, MD 
Associate Clinical Professor, Department of Medicine
University of California, Los Angeles
David Geffen School of Medicine
Co-Director of the Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles

Dr. Richard S. Finn is an Associate Clinical Professor of Medicine at the UCLA David Geffen School of Medicine in the division of hematology/oncology and co-director of the signal transduction and therapeutics program in the Jonsson Comprehensive Cancer Center at UCLA.  Dr. Finn currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in cancer. Dr Finn has served as principal investigator in several trials exploring the use of targeted therapies in breast and liver cancers. Most recently, he has lead the development of palbociclib from pre-clinical laboratory work to its US Food and Drug Administration approval for advanced estrogen receptor positive–breast cancer. His work has been published in the Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, Cancer Research, and Clinical Cancer Research, among other journals. 

As an undergraduate student at UCLA, he was involved with early studies in the laboratory of Dr. Dennis Slamon investigating the HER2 oncogene and the development of monoclonal antibodies to this target in breast cancer. He earned an MD degree at the University of Southern California Keck School of Medicine, then returned to UCLA for clinical training in internal medicine and hematology/oncology.

DISCLOSURE OF CONFLICTS OF INTEREST
Richard S. Finn, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee: Bayer Pharmaceuticals Corporation; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Pfizer, Inc.


Lori J. Goldstein, MD
Professor of Medicine, Department of Hematology Oncology
Director of the Naomi and Phil Lippincott Breast Evaluation Center
Deputy Associate Director of Clinical Research
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Dr. Lori J. Goldstein is a Professor of Medicine in the Department of Hematology Oncology at Fox Chase Cancer Center. She is also the Director of the Naomi and Phil Lippincott Breast Evaluation Center at Fox Chase Cancer Center and the breast cancer research program. Under her leadership, the Breast Evaluation Center received full accreditation from the National Accreditation Program for Breast Centers in 2009 and 2012. Dr. Goldstein also serves as Deputy Associate Director of clinical research.

Dr. Goldstein established the Breast Cancer Survivorship Clinic. She is the Fox Chase Cancer Center’s principal investigator for the Eastern Cooperative Oncology Group and is a founding member of the National Comprehensive Cancer Network breast cancer guidelines panel. Dr. Goldstein has authored numerous publications in The New England Journal of Medicine, Journal of Clinical Oncology, Breast Cancer Quarterly, and Clinical Breast Cancer

Dr. Goldstein earned an MD degree from the State University of New York Upstate Medical Center. Dr. Goldstein completed fellowship training at the National Cancer Institute Division of Cancer Biology and Diagnosis, National Institutes of Health in Bethesda, Maryland.

DISCLOSURE OF CONFLICTS OF INTEREST
Lori J. Goldstein, MD, FASCO, reported a financial interest/relationship or affiliation in the form of Research grant: Dompe Pharmaceuticals; Advisory board: Novartis Pharmaceuticals Corporation; Prometris/Roche; Synta Pharmaceuticals Corp.


Virginia G. Kaklamani, MD, DSc
Professor of Medicine, Division of Hematology/Oncology
University of Texas Health Sciences Center
Leader of the Breast Cancer Program
Cancer Therapy and Research Center
San Antonio

Dr. Virginia G. Kaklamani is Professor of Medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center in San Antonio and is Leader of the breast cancer program at the Cancer Therapy and Research Center. She was Head of the Translational Breast Cancer Program and Co-Director of the cancer genetics program at Northwestern University. 

Dr. Kaklamani’s research interests include studying families at high risk for cancer and identifying genetic mutations that are associated with an increased risk for breast, colon, and prostate cancer. She identified several genetic mutations related to obesity that increase the risk for breast cancer.  

She earned an MD degree with honors from the University of Athens and completed a residency in internal medicine at Newton-Wellesley Hospital in Boston, Massachusetts. Dr. Kaklamani completed fellowship training in hematology/oncology at Northwestern University, where she earned an MS degree in clinical investigation. 

DISCLOSURE OF CONFLICTS OF INTEREST
Virginia G. Kaklamani, MD, DSc, reported a financial interest/relationship or affiliation in the form of Advisory board: Celgene Corporation; Eisai Inc.; Speaker: Novartis Pharmaceuticals Corporation.


Ian E. Krop, MD, PhD
Director of Clinical Research for the Breast Oncology Center
Senior Physician
Dana-Farber/Brigham and Women’s Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Ian E. Krop is the Director of Clinical Research for the Breast Oncology Center and Senior Physician at Dana-Farber/Brigham and Women’s Cancer Center and an Assistant Professor of Medicine at Harvard Medical School in Boston, Massachusetts. He is a translational researcher focused on elucidating mechanisms of resistance to targeted therapies and developing novel therapeutic approaches to overcome this resistance. The majority of his work has been in the area of HER2-positive breast cancer, and he has been a leader in the development of the HER-directed antibody-drug conjugate trastuzumab emtansine. 

Dr. Krop co-chairs the Dana-Farber Cancer Institute Scientific Review Committee and the HER2 working group of the Translational Breast Cancer Research Consortium and is a member of the Eastern Cooperative Oncology Group Data Monitoring Committee and the Susan G. Komen for the Cure Scientific Advisory Council. He is the recipient of the 2005 Dunkin Donuts Rising Stars Award and the 2012 Dana-Farber Clinical Faculty Innovation Award. 

Dr. Krop earned an MD degree from John Hopkins University School of Medicine. He trained at John Hopkins Hospital, Dana-Farber Cancer Center, Harvard Medical School, and Brigham and Women’s Hospital. He completed a medical oncology fellowship at Dana-Farber Cancer Center.

DISCLOSURE OF CONFLICTS OF INTEREST
Ian E. Krop, MD, PhD, reported a financial interest/relationship or affiliation in the form of Research grant: Genentech/Roche.


Ruth M. O’Regan, MD
Division Head of Hematology and Oncology
University of Wisconsin School of Medicine and Public Health
Madiso
n

Dr. Ruth M. O’Regan is the Division Head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health. She is an internationally recognized physician and researcher with particular expertise on breast cancers that are resistant to current therapies.  A native of Dublin, Ireland, Dr. O’Regan previously was a Professor of Hematology and Medical Oncology at Emory University in Atlanta, Georgia, where she held the Louisa and Rand Glenn Family Chair in Breast Cancer Research. Additionally, she was the Medical Director at Glenn Family Breast Center of Emory University, Director of the Breast Cancer Translational Research Program at the Winship Cancer Institute, and Chief of Hematology and Medical Oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital.

In her dedication to training the next generation of physicians, Dr. O’Regan served as Vice Chair for educational affairs in the Department of Hematology and Medical Oncology and as Director of the hematology/oncology fellowship program at Emory University.  With a highly active research program focused on identifying mechanisms of resistance to breast cancer therapies and development of new therapies, Dr. O’Regan has been principal investigator for numerous grants and clinical trials. Her research group has made significant discoveries about the role of the PI3 kinase-mTOR pathway in triple-negative breast cancer, showing that mTOR inhibition can sensitize breast cancer cells to upstream growth factor inhibitors. These discoveries resulted in a novel clinical trial for patients with metastatic breast cancer.

Dr. O’Regan earned an MD degree at University College (Dublin, Ireland) and completed residency programs at Mater Hospital (Dublin, Ireland), the Medical College (Milwaukee, Wisconsin), and Northwestern University (Chicago). 

DISCLOSURE OF CONFLICTS OF INTEREST
Ruth M. O'Regan, MD, reported a financial interest/relationship or affiliation in the form of Advisor: AstraZeneca Pharmaceuticals LP; Pfizer, Inc.; Advisor/Research: Genentech, Inc.; Novartis Pharmaceuticals Corporation.


Priya Rastogi, MD
Assistant Professor of Medicine
University of Pittsburgh School of Medicine
Medical Oncologist
Magee-Womens Hospital of UPMC
Senior Associate Medical Director and Vice-Chair for Medical Affairs
National Surgical Adjuvant Breast and Bowel Project Foundation
Pittsburgh, Pennsylvania

Dr. Priya Rastogi is an Assistant Professor of Medicine at the University of Pittsburgh School of Medicine. Board certified in internal medicine and medical oncology, Dr. Rastogi specializes in the diagnosis, treatment, and prevention of breast cancer at Magee-Womens Hospital of UPMC.  She serves as Senior Associate Medical Director and Vice-Chair for Medical Affairs with the National Surgical Breast and Bowel Project and as the protocol officer for phase 2 and phase 3 adjuvant and neoadjuvant breast cancer clinical trials. Conducting her own research with NSABP, Dr. Rastogi examined the risk for congestive heart failure in women who received the drug herceptin in combination with chemotherapy.

Dr. Rastogi is an associate member of the American Society of Clinical Oncology and the American Association for Cancer Research and has several abstracts and research articles in leading journals, including the Journal of Clinical Oncology, Clinical Breast Cancer, Oncology, The New England Journal of Medicine, Oncology Nurse Forum, Menopause, and Breast Cancer Research Treatment.

Dr. Rastogi earned an MD degree from Wright State University School of Medicine in Dayton, Ohio. She completed her internal medicine residency at Saint Joseph's Hospital in Denver, Colorado, where she received the Resident of the Year Award.

DISCLOSURE OF CONFLICTS OF INTEREST
Priya Rastogi, MD, has no real or apparent conflicts of interest to report.


Hope S. Rugo, MD
Professor of Medicine 
Director, Breast Oncology and Clinical Trials Education 
University of California San Francisco Helen Diller Family
Comprehensive Cancer Center 
San Francisco

Dr. Hope S. Rugo is a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, where she directs breast cancer and clinical trial education. Her research interests include novel therapies for advanced breast cancer, immunomodulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy, and supportive care. 

Dr. Rugo is a member of the Breast Oncology Program at the UCSF Breast Cancer Center, an investigator in the national multicenter ISPY2 trial, and is the principal investigator of a number of clinical trials. She is one of three recipients of a Komen Promise Award, receives funding from the Breast Cancer Research Foundation, and serves on a number of steering committees for national and international trials. Dr. Rugo is a member of the ALLIANCE Breast Core Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the National Comprehensive Cancer Network guidelines committee, and serves on several committees for the American Society of Clinical Oncology. She has published many peer-reviewed papers and has given presentations on a variety of cancer related topics. 

Dr. Rugo earned an MD degree from the University of Pennsylvania School of Medicine and completed both a residency in internal medicine and fellowship in hematology and oncology at the UCSF. Additionally, she completed a 2-year post-doctoral fellowship in immunology at Stanford University. 

DISCLOSURE OF CONFLICTS OF INTEREST
Hope S. Rugo, MD, reported a financial interest/relationship or affiliation in the form of Research to UC Regents only: Amgen, Inc.; Celsion Corporation; Eisai Inc.; Genentech/Roche; GlaxoSmithKline; MacroGenics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Optimer Biotechnologies, Inc.; Pfizer, Inc.; Plexxikon; Speaker: Genomic Health, Inc.


Antoinette R. Tan, MD
Chief of Breast Medical Oncology
Co-Director of the Phase I Program
Levine Cancer Institute
Carolinas Healthcare System
Clinical Professor, Department of Medicine
University of North Carolina
Charlotte

Dr. Antoinette R. Tan is the Chief of Breast Medical Oncology and Co-Director of the Phase I Program at Levine Cancer Institute, Carolinas HealthCare System in Charlotte, North Carolina. She is Chief of medical oncology at Carolinas HealthCare System’s Carolinas Medical Center-Pineville location. She is also a Clinical Professor in the Department of Medicine at the University of North Carolina. 

Prior to joining Levine Cancer Institute, Dr. Tan was an Associate Professor of Medicine at Rutgers Cancer Institute of New Jersey. In 2010, she was appointed Director of Phase I and Investigational Therapeutics at Rutgers Cancer Institute of New Jersey. Her research interests focus on targeted treatments for breast cancer and drug development. She has extensive experience in early phase clinical trials and breast cancer studies. 

Dr. Tan earned an MD degree from Rutgers-Robert Wood Johnson Medical School through an accelerated BA/MD program. After completing her internship and residency in internal medicine at North Shore University Hospital–New York University School of Medicine and Memorial Sloan Kettering Cancer Center, she completed an oncology fellowship at the National Cancer Institute. Dr. Tan also obtained formal training in clinical research during her fellowship and earned an M.S. in health sciences from Duke University School of Medicine. 

DISCLOSURE OF CONFLICTS OF INTEREST
Antoinette R. Tan, MD, MHSc, reported a financial interest/relationship or affiliation in the form of Contracted research: Genentech, Inc.


Deborah L. Toppmeyer, MD
Chief Medical Officer and Director
Stacy Goldstein Breast Cancer Center
Hereditary Oncology Prevention and Evaluation Center at
Rutgers Cancer Institute of New Jersey
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick

Deborah L. Toppmeyer is the Chief Medical Officer and Director of both the Stacy Goldstein Breast Cancer Center and the Hereditary Oncology Prevention and Evaluation Center at Rutgers Cancer Institute of New Jersey. She is also a Professor of Medicine at Rutgers Robert Wood Johnson Medical School.  

Dr. Toppmeyer’s research interests include clinical trial design and implementation of novel targeted therapies in advanced disease and neoadjuvant trials in triple-negative breast cancer.  She also has a strong interest in cancer genetics, including clinical trials and educational initiatives developed for the high-risk population. Dr. Toppmeyer is the author or coauthor of more than 40 publications and serves on the editorial board of Clinical Cancer Research. She also serves as a core member of the ECOG-ACRIN breast committee and is a member of American College of Radiology Appropriateness Criteria Program.  

Dr. Toppmeyer earned an MD degree from Albany Medical College and completed her internship and residency in internal medicine at the University of Pittsburgh, School of Medicine followed by a 2-year research fellowship in the Physician Investigator Fellowship Training Program.  She completed her medical oncology fellowship at Dana Farber Cancer Institute. 

DISCLOSURE OF CONFLICTS OF INTEREST
Deborah L. Toppmeyer, MD, reported a financial interest/relationship or affiliation in the form of Stocks: Novartis Pharmaceuticals Corporation (Speaker and Spouse).